🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Recurrent Atypical Teratoid/Rhabdoid Tumor

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors NCT07664176Phase 11 site📍 Washington D.C. Children's National Research Institute · Tests: NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors NCT04185038Phase 11 site📍 Seattle Seattle Children's Hospital · Tests: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388Phase 13 sites📍 Birmingham📍 St Louis📍 Houston M.D. Anderson Cancer Center · Tests: G207 A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161Phase 216 sites📍 Los Angeles📍 Palo Alto📍 Washington D.C. Memorial Sloan Kettering Cancer Center · Tests: Selinexor Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) NCT06193759Phase 11 site📍 Washington D.C. Children's National Research Institute · Tests: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized… A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors NCT05135975Phase 26 sites📍 Birmingham📍 Aurora📍 Washington D.C. Nationwide Children's Hospital · Tests: Cabozantinib B7-H3.CD28Z.CART in CNS Neoplasms NCT07390539Phase 12 sites📍 Boston📍 Boston Robbie Majzner · Tests: B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702Phase 1, Phase 210 sites📍 Palo Alto📍 Aurora📍 Washington D.C. St. Jude Children's Research Hospital · Tests: Onivyde, Talazoparib, Temozolomide Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082Phase 11 site📍 Bethesda Jazz Pharmaceuticals · Tests: ONC206 Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) NCT07447076Phase 22 sites📍 San Francisco📍 San Francisco Sabine Mueller, MD, PhD · Tests: Lumber Puncture, Blood Specimen Collection, Magnetic resonance imaging (MRI), Gemcitabine, Paxalisib GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults NCT07087002Phase 11 site📍 Palo Alto Stanford University · Tests: GPC2-CAR T cells, Fludarabine, Cyclophosphamide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy